Business Wire

TSUNO-GROUP

31.1.2024 08:16:27 CET | Business Wire | Press release

Share
Tsuno Group successfully developed and applied for a patent for a stable formulation with a high dosage of FERULIC ACID, a rare natural plant-derived ingredient having the function of absorbing UV.

Tsuno Group Co., Ltd., headquartered in Katsuragi-cho, Ito-gun, Wakayama, and led by President: Fumi Tsuno and Matsumoto Trading Co., Ltd., headquartered in Chuo-ku, Tokyo, with CEO Shunsuke Matsumoto have successfully developed a new sunscreen formulation with Ferulic Acid. Ferulic Acid is a rare natural plant-derived UV absorber that has been difficult in stability and solubility at the high concentrations of ferulic acid.

For ferulic acid

Tsuno Group was the first in the world to successfully produce large amounts of ferulic acid, a polyphenol, from rice bran. Ferulic acid possesses strong antioxidant properties and has been recognized for its potential to prevent Alzheimer's disease, diabetes mellitus, and high cholesterol. It can also be used as a raw material for producing natural vanillin, a vanilla flavoring. In cosmetics, it inhibits melanin production by blocking tyrosinase activity and has anti-inflammatory, antimicrobial, and antioxidant properties. Therefore, it has been used as an active ingredient in a variety of cosmetic products.

“We, as a leading company in rice & bran chemistry in the world, have been developing a number of functional products with tremendous efforts through accumulating technologies, have also researched their safe levels and effects to be well accepted in pharma, food, feed and cosmetic industries. Now we have launched a technology of using ferulic acid from rice bran as a natural antioxidant and UV absorber, which is the first innovation ever in the world. We are confident that you shall discover this product as unique and impactful to contribute not only to the human health and beauty but the circular economy for the world.” —— Fumi Tsuno, President of Tsuno Group Co., Ltd.

UV absorption effect of ferulic acid

Ethylhexyl methoxycinnamate (EHMC), a petrochemical UV filter, is most widely used in sunscreen applications. However, recent studies have shown its negative impact on the aquatic environment, including coral bleaching. Ferulic acid, a naturally derived sunscreen ingredient from rice, absorbs UV rays in a similar range of the spectrum as octyl methoxycinnamate (OMC). This promising characteristic makes it a potential eco-friendly alternative to EHMC. Amidst growing global concerns about environmental sustainability, ferulic acid's potential as a natural and effective sunscreen ingredient is likely to gain increased recognition. It holds significant potential for application in a wide range of cosmetic products throughout Japan.

Development of high stability formulation of UV-care products with high concentration of Ferulic Acid

Gaining recognition for its UV-absorbing properties, ferulic acid, a rare natural plant-derived ingredient, presents challenges in solubility and stability at the high concentrations for sunscreen formulations. To overcome these hurdles, Matsumoto Trading has dedicated research and development, pioneering an innovative technology utilizing a high concentration of ferulic acid in a solid stick formulation. This novel formulation has been developed with SPF50+ and PA++ (in vitro) containing only ferulic acid, a natural UV absorber extracted from rice bran. This unique formulation eliminates the need for other commonly used UV protective ingredients, while maintaining high sun protection effectiveness. Patent pending.

About Tsuno Rice Fine Chemicals Co., Ltd.

Tsuno Rice Fine Chemicals manufactures various ingredients from by-products generated in the process of refining rice bran oil, and they can be used for pharmaceutical, cosmetic, functional foods, food additives, feedstock, and industrial chemicals. In addition, we are also engaged in the manufacture of cosmetics under our own brand that incorporate these ingredients.

Business Profile of Tsuno Group Co., Ltd.

We are promoting the advanced and effective use of rice bran, a symbol of health and beauty that has been popular since ancient times. We are developing three businesses: the Rice Bran Oil Production Business, the Fine Chemicals Business, and the Oleo Chemical Business.

Established: February 1, 1947
Representative Director and President Fumi Tsuno
URL : https://www.tsuno.co.jp/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240130923907/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release

Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor

Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release

With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f

Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release

Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th

Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release

Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye